These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 22632377

  • 1. Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
    Blomström-Lundqvist C, Blomström P.
    Expert Opin Drug Saf; 2012 Jul; 11(4):671-9. PubMed ID: 22632377
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 28; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 4. Vernakalant for the conversion of atrial fibrillation: the new kid on the block?
    Conde D, Baranchuk A.
    Ann Noninvasive Electrocardiol; 2014 Jul 28; 19(4):299-302. PubMed ID: 24738652
    [Abstract] [Full Text] [Related]

  • 5. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D.
    Int J Cardiol; 2013 Oct 30; 169(2):95-6. PubMed ID: 24071384
    [Abstract] [Full Text] [Related]

  • 6. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.
    Cardiovasc Ther; 2013 Oct 30; 31(5):e55-62. PubMed ID: 23398692
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May 30; 21(127):119-22. PubMed ID: 22827000
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W, Guo X, Wang Q, Sun G, Wang J.
    J Cardiovasc Pharmacol; 2020 Jul 30; 76(1):32-41. PubMed ID: 32251022
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 30; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y, Dobrev D.
    Vasc Health Risk Manag; 2013 Jun 30; 9():165-75. PubMed ID: 23637539
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A.
    Drugs; 2004 Jun 30; 64(24):2741-62. PubMed ID: 15563247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.